U.S. FDA to not conduct advisers’ meet for Sarepta’s Duchenne gene therapy

(Reuters) – Sarepta Therapeutics said on Friday that the U.S. FDA will not conduct a meeting of its advisers and will do a priority review for traditional approval of its gene therapy Elevidys for a muscle wasting disorder.

(Reporting by Christy Santhosh)